Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group. - Immunotherapy with anti-PD in stage III melanoma

Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc0 个研究点目标入组 900 人开始时间: 2015年11月13日最近更新: 2024年7月15日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 900

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- At least 18 years of age.
•- Complete resection of Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC. No past or current in-transit metastases or satellitosis.
•- Melanoma with unknown origin of the primary is eligible
•- Mandatory to ship tumor sample for evaluation of PD-L1 expression.
•- The maximum duration from surgery to first study drug treatment is 13 weeks. Treatment should start only after complete wound healing from the surgery.
•Note: if there is a delay of 1-7 days exceeding 13 weeks due to extreme unforeseen circumstances, the eligibility should be discussed with the medical monitor.
•- Disease status for the post-surgery baseline assessment must be documented by full Chest/Abdomen/Pelvis CT and/or MRI with Neck CT and/or MRI (for Head and Neck primaries) and complete clinical examination after the informed consent and prior to enrollment.
•Note: if a patient had laboratory/imaging tests as part of local routine guidelines (standard of care) prior to signing informed consent, the procedures will be acceptable for screening purposes if they are within the window required by the protocol.
•- Disease-free (no loco-regional relapse or distant metastasis); no clinical evidence for brain metastases.
•- BRAF mutation status (known or not done).
•- ECOG performance status of 0 or 1.
•- Patient demonstrates adequate organ function as defined in the protocol
•- Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment.
•- WOCBP should use adequate birth control methods.
•- Female patients who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 120 days after the last dose of study drug .
•- Patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
•Please refer to the Diagnosis and Main Criteria for Inclusion in the Protocol for the full list of inclusion criteria.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 738
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 162

排除标准

•- Mucosal or ocular melanoma.
•- Prior therapy for melanoma except surgery for primary melanoma lesions.
•- history of (non-infectious) pneumonitis that required steroids or current pneumonitis. History of or current interstitial lung disease.
•- history of another malignancy or a concurrent malignancy. Exceptions include patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
•- active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
•- active infection requiring therapy.
•- diagnosis of immunodeficiency, no systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
•- known history of human immunodeficiency virus (HIV), active Hepatitis B or Hepatitis C.
•- treatment with live vaccines within 30 days prior to the first dose of study medication are not eligible.
•- prior treatment with any anti-CTLA4 monoclonal antibody or anti-PD-1, or PD-L1 or PD-L2 agent.
•- Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks prior to the first dose of treatment
•- patient is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
•- female patients who are Breast feeding

研究者

发起方

Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc

相似试验

进行中（未招募）

1 期

Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resectioStage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mmany Stage IIIB or IIIC (no in-transit metastases)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-004944-37-PLMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900

进行中（未招募）

3 期

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

2023-509136-25-00Merck Sharp & Dohme LLC572

招募中

3 期

NL-OMON56050Merck Sharp & Dohme (MSD)108

进行中（未招募）

1 期

EUCTR2014-004944-37-DKMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900

进行中（未招募）

1 期

EUCTR2014-004944-37-NLMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900